Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering
July 23, 2020 12:45 ET
|
Immuron Limited
MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing...
Immuron Announces $20.0 Million Registered Direct Offering
July 21, 2020 08:45 ET
|
Immuron Limited
MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points
July 21, 2020 07:00 ET
|
Immuron Limited
Immuron’s IMM-124E used to manufacture Travelan® and Protectyn® demonstrates antiviral activity against the COVID-19 virus in laboratory studiesImmuron’s technology platform offers a potential new...
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic
July 20, 2020 06:00 ET
|
Immuron Limited
Key Points NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial will...
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
June 19, 2020 06:00 ET
|
Immuron Limited
Key Points Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc.Immuron executes a Research Agreement with CSIRO to develop a new oral...
US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea
June 09, 2020 06:00 ET
|
Immuron Limited
Key Points NMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial...
Immuron Board Relinquish Cash Payment of Fees
April 28, 2020 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, April 28, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron North American Travelan® Sales Up 95%, Global Sales Up 60%
April 20, 2020 06:00 ET
|
Immuron Limited
Key Highlights: North American sales up by 95% YoY in Q3 FY20Immuron achieved 60% YoY growth in worldwide product sales in Q3 FY20.YTD March 31, FY20 worldwide sales reached AU $2.67M, increasing 57%...
Resignation of CEO & Director and cost cutting amidst COVID-19
March 25, 2020 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, March 25, 2020 (GLOBE NEWSWIRE) -- The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the...
Immuron Provides Update on First Half of FY20 Results
March 03, 2020 07:00 ET
|
Immuron Limited
Key Highlights: Strong continued growth of Travelan® sales reported in all marketsGlobal sales reached USD $1.1 million (AUD $1.68 million) for first half FY 2020 up 55% from first half FY 2019North...